Loading data...
EVA Therapeutics Inc.
CEO
Hiroshi Ozaki
Saving the lives of newborns with underdeveloped lungs using enteral ventilation technology.
Recent News & PR
Summary
Message to Participants
Detailed Information
EVA Therapeutics Inc. has developed a new medical technology called 'EVA Method' that utilizes gas exchange from the intestines, aiming to treat newborns with underdeveloped lungs. This innovative intestinal respiration system is currently undergoing clinical trials to improve hypoxic conditions.
Unfair Advantage & Strengths
N/A
Competitors
N/A
Company Profile
事業カテゴリ
Healthcare / Biotech, DeepTech
本社所在地
1F Chotokuji Bldg., 1-4-6 Doshin, Kita-ku, Osaka, Japan
設立日
20210601
資本金
1億円
Industry Outlook & Trends for EVA Therapeutics Inc.
Driven by aging populations and rising healthcare costs, the healthcare and biotech market where EVA Therapeutics Inc. operates is growing globally. Telemedicine, digital health via wearables, AI-driven drug discovery, and gene therapy are advancing rapidly. The industry is shifting from treatment to prevention, increasing demand for highly personalized health solutions like those developed by EVA Therapeutics Inc..
🔒
VPO Investor Pro Features
You are viewing a basic startup profile. Create a free account to access the dashboard. You can also upgrade to the "Investor Pro" plan to unlock full access to the following premium databases and features:
🎬
Elevator & Full Pitch Video
Watch full presentations with English/Japanese subtitles.
📊
AI Quick Report & Valuation
Get AI-driven assessment scores on market, product, and traction.
📅
Priority Challenges & Hiring
Access core corporate bottlenecks and current hiring plans.
📝
Full Transcripts
Read full pitch dialogue in both English and Japanese.
📈
Financials & Exit Strategy
Unlock IPO/M&A timelines and debt/equity plans.
👥
Advisors & Key Members
View internal team details and advisory board configurations.